Hereditary Genetic Testing Market By Test Type (Predictive Testing, Carrier Testing, Prenatal and Newborn Testing, Diagnostic Testing, Pharmacogenomic Testing, Nutri-genomic Testing), By Application (Cancer, Genetic Disease, Cardiovascular Disease), Industry Analysis Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast, 2019 - 2027

Hereditary Genetic Testing Market definition and Estimation

Genetic testing additionally called as DNA testing is a sort of medical trial that recognize changes in proteins, qualities or chromosomes. The test outcomes can affirm or preclude an estimated basic genetic condition or help in deciding a person's possibility of creating or passing on a hereditary problem.

 The hereditary Genetic Testing Market is predicted to grow at a CAGR of 10.1 % , from $ 12,682 million in 2019 to $ 21,260 million in 2027.    

Hereditary Genetic Testing Market Overview

 The hereditary Genetic testing market is drawn out and requires the experience of genetic instructors and medical geneticists to help with choosing the most appropriate test for a patient. Also, advances and upgrades in Genetic testing innovation are significantly affecting the market development as these tests precisely analyze various diseases. Moreover, the COVID-19 outbreak impartially affects the Hereditary Genetic testing market, attributable to a decrease in test methodology because of lockdown in practically all parts of the world. The adverse effects of the pandemic on the market took a turn during this pandemic which affected the market on large scale.

The worldwide Hereditary Genetic testing market is relied upon to enlist generous development later on, attributable to ascend in incidents of hereditary disorders and malignancy and ascend in acceptance and acknowledgment of medicines. For example, genetic testing has been broadly utilized in pharmacogenomics, likewise eluded as drug quality testing. Also, progressions in hereditary genetic testing techniques are relied upon to support the genetic testing market development during the forecast period . For example, the Healthcare system in non-industrial countries, for example, Brazil, India, and China have encountered a critical expansion in investments in medical care and infrastructure, which prompts flood popularity for genetic testing around there.

Hereditary Genetic Testing Market Segmentation

By Type

• Predictive & Presymptomatic Testing
• Carrier Testing
• Prenatal & Newborn Testing
• Diagnostic Testing
• Pharmacogenomic Testing
• Others

By Technology

• Cytogenetic Testing
• Biochemical Testing
• Molecular Testing 

By Application

• Cancer diagnosis
• Genetic Disease Diagnosis
• Cardiovascular Disease Diagnosis

By Type:

By type, the Hereditary Genetic testing market is segmented into prescient testing and presymptomatic testing, Carrier Testing, pre-natal and newborn testing, diagnostics testing, pharmacogenomics testing, and others. The pre-birth and newborn testing fragment stood firm on predominant foothold with most noteworthy revenue, and is required to keep up its strength during the forecast. This is owing to development in awareness among individuals with respect to medical care and expansion in rates of death rate from genetic sicknesses across the world. Then again, the pharmacogenomics testing part is expected to witness most noteworthy CAGR during the forecast period.

By Technology:

The atomic testing section obtained the major hereditary genetic testing share of the overall industry and is relied upon to keep a lead during the forecast time frame. The development of this segment is credited to the way that sub-atomic testing is the most utilized technology for genetic testing. For example, the technology is utilized in hereditary tests, for example, carrier testing, demonstrative testing, prescient and presymptomatic testing, and others. Moreover, molecular testing is preferred, liked as it very well be utilized to analyze gains or misfortunes in DNA that are not distinguishable with routine chromosome analysis.

Hereditary Genetic Testing Market Geography Overview

Region wise, North America was the main revenue supporter of the global hereditary genetic testing market, and was relied upon to rule the market during the forecast period. North America hereditary genetic testing market size was over USD 8.5 billion of every 2020 by virtue of the rising number of malignant growth cases and other ongoing sicknesses just as quickly developing older populace base. 

 In any case, Asia-Pacific is relied upon to develop at the most noteworthy CAGR during the estimated time, inferable from expansion in affordability, flood in medical services use, and ascend unawareness toward early screening of genetic issues.   Moreover, expanding acknowledgment of new technologies, rising patient awareness for early sickness diagnosis and developing frequency of genetic infections will help the general hereditary Genetic testing market expansion.

Hereditary Genetic Testing Market DORC:

Growth Drivers -

• Rising Prevalence of Genetic Disorders
• Increasing Prevalence of Various Types of Cancer, Globally
• Increasing Research Funding in the Field of Genomics

Market Challenges -

• Expensive Sequencing Procedures and Their Applications in Medical Treatments
• High Capital Requirement Hampering the Expansion of Global Reach
• Stringent Regulatory Standards

Market Opportunities -

• Technological Advancements for Exome Sequencing
• Rise of Direct-to-Consumer (DTC) Testing Services
• Massive Scope for Adoption of NGS-Based in Emerging Nations

Key Players:

The worldwide hereditary genetic testing have profoundly aggressive and the noticeable parts in the market have embraced different systems to collect greatest genetic testing share of the overall market. Major key players working in the market incorporate Abbott Laboratories, Bio-Rad Laboratories, Inc. (raindance Technologies, Inc.), Myriad Genetics, Inc. (Bunch RBM, Inc.), Danaher Corporation (Cepheid), F. Hoffmann-La Roche Ltd., Eurofins Scientific, Illumina, Inc., Qiagen N.V., Thermo Fisher Scientific, Inc., and CSL Ltd.

Recent News & Developments:

• Ambry Genetics and Intalere Teams partnered in April 2019. As a result of this partnership, the firm was able to have greater access to healthcare facilities with genetic research in order to better treat patients with elevated cancer risks
• 23andMe announced the introduction of a novel genetic test in March 2018 that assesses the risk of type 2 diabetes. The company's customer base and market share have grown as a result of this launch.

Frequently Asked Questions (FAQs)

Related Reports